1. Home
  2. RBBN vs CTNM Comparison

RBBN vs CTNM Comparison

Compare RBBN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$2.83

Market Cap

493.4M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.53

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBBN
CTNM
Founded
1997
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
493.4M
489.4M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
RBBN
CTNM
Price
$2.83
$11.53
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$4.67
$19.00
AVG Volume (30 Days)
1.1M
158.6K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.97
N/A
Revenue Next Year
$6.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$3.57
52 Week High
$4.29
$16.33

Technical Indicators

Market Signals
Indicator
RBBN
CTNM
Relative Strength Index (RSI) 50.09 33.95
Support Level $2.72 $10.17
Resistance Level $2.90 $13.26
Average True Range (ATR) 0.20 0.74
MACD 0.01 -0.22
Stochastic Oscillator 34.73 0.58

Price Performance

Historical Comparison
RBBN
CTNM

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: